Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative return of over 20% within the next six months [7][17]. Core Insights - The company achieved a revenue of 4.01 billion yuan in 2024, representing a year-on-year growth of 19.22%, while the net profit attributable to shareholders was 601.57 million yuan, up 3.71% year-on-year [1]. - In Q1 2025, the company reported a revenue of 1.06 billion yuan, a slight decline of 2.64% year-on-year, with a net profit of 200 million yuan, showing a marginal increase of 0.03% [1]. - The sales expense ratio increased to 36.71% in 2024, primarily due to higher promotional costs for newly launched products [2]. - The company is focusing on optimizing its revenue structure, with a notable increase in the proportion of patented and new products, which are expected to drive future growth [3]. Financial Performance - The company’s revenue for 2025 is projected to be 4.54 billion yuan, with a growth rate of 13.10%, and net profit is expected to be 661.81 million yuan, reflecting a growth rate of 10.01% [5][11]. - The R&D investment for 2024 was 1.02 billion yuan, accounting for 25.35% of revenue, indicating a strong commitment to innovation [4]. - The company’s EBITDA for 2024 is estimated at 1.73 billion yuan, with a net profit margin of 14.99% [11][12]. Product and Pipeline Development - The company has four projects in the NDA stage and three in Phase III clinical trials, showcasing a robust pipeline for future growth [4]. - New products such as复立坦 and 信立汀他 have entered the national medical insurance catalog, laying a foundation for future sales growth [3]. Market Position and Strategy - The company is increasing its market presence through enhanced sales efforts and product promotion, particularly in the competitive hypertension medication market [3][4]. - The revenue from formulations reached 3.19 billion yuan in 2024, up 20.43%, while raw materials and intermediates saw a slight decline [3].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7]. Core Views - In 2024, the company achieved operating revenue of 5.37 billion yuan, a year-on-year decline of 11.6%, and a net profit attributable to shareholders of 170 million yuan, down 70.6% year-on-year. In Q4 2024, the operating revenue was 1.5 billion yuan, a decrease of 19.3% year-on-year, with a net profit of -190 million yuan [2][4]. - For Q1 2025, the company reported operating revenue of 1.08 billion yuan, a year-on-year decline of 20.8%, and a net profit of 100 million yuan, down 58.1% year-on-year [2][4]. - The company is focusing on overall resource efficiency and is undergoing a phase of adjustment in its skincare business, while the raw material business is growing steadily, and the high-margin medical terminal business is expanding rapidly [9]. Summary by Sections Financial Performance - In 2024, the raw material business generated revenue of 1.24 billion yuan, up 9.5% year-on-year, with international market expansion showing a growth of 17.7%, particularly in the Americas, Europe, and Southeast Asia, where growth exceeded 20% [9]. - The medical terminal business achieved revenue of 1.44 billion yuan, a year-on-year increase of 32%, with skin-related medical products growing by 43.6% [9]. - The functional skincare business reported revenue of 2.57 billion yuan, down 31.6% year-on-year, while the nutritional science business generated 80 million yuan, up 41% year-on-year [9]. Cost and Profitability - The company's gross margin improved by 0.8 percentage points year-on-year, with the raw material, medical terminal, and functional skincare gross margins changing by 0.9, 2.3, and -1.1 percentage points respectively [9]. - The net profit margin decreased by 6.5 percentage points year-on-year due to increased management expenses and changes in the organizational structure [9]. Future Outlook - The company is expected to see improvements in revenue and profit as it continues to adjust its skincare business and launch new products. The raw material business is expected to maintain a strong market position, and the medical beauty business is gradually contributing more to overall performance [9]. - EPS forecasts for 2025-2027 are 0.95, 1.33, and 1.67 yuan per share respectively [9].

[Table_Title] 研究报告 Research Report 26 May 2025 潮宏基 CHJ Industry (002345 CH) 店均高速增长，开店节奏稳健，注重品牌系统性工程建设 yy.kou@htisec.com ashley.fy.chen@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件：5 月 23 日，海通国际海外消费组调研潮宏基总部，参加公司高管交流会。公司管理层表示终端增速自 2024 年 四季度开始提升，2025 年 4 月份店均增速约 45%，5 月初至 5 月 20 日增速约为 30%。5 月门店人流量在五一假期后 有所下滑，主要是受节日透支效应影响。 差异化打法应对市场竞争，产品设计突出年轻时尚风格。面对激烈市场竞争，管理层表示，其产品始终坚持差异化 定位，不做纯粹的"量+价"竞争，更重视客户体验和品牌美誉度。公司聚焦年轻消费群体，20-40 岁消费者占比约 80%，其中 25-35 岁区间为核心人 ...

Investment Rating - The report maintains a "Buy" rating for the company [5][7]. Core Views - The company achieved a revenue of 4.012 billion yuan in 2024, representing a year-on-year growth of 19.22%, while the net profit attributable to the parent company was 601.57 million yuan, up 3.71% year-on-year [1]. - In Q1 2025, the company reported a revenue of 1.062 billion yuan, a slight decline of 2.64% year-on-year, with a net profit of 200 million yuan, showing a marginal increase of 0.03% [1]. - The sales expense ratio increased to 36.71% in 2024, primarily due to higher promotional costs for newly launched products [2]. - The revenue structure is shifting towards patented and new products, with a notable increase in the revenue scale of these segments [3]. - The company invested 1.017 billion yuan in R&D in 2024, accounting for 25.35% of its revenue, indicating a strong commitment to innovation [4]. Financial Performance - The projected revenues for 2025, 2026, and 2027 are 4.538 billion, 5.423 billion, and 6.246 billion yuan, respectively, with net profits adjusted to 662 million and 783 million yuan for 2025 and 2026 [5]. - The company’s EBITDA for 2024 is estimated at 1.727 billion yuan, with a net profit margin of 14.99% [6][11]. - The company’s total assets are projected to reach 10.168 billion yuan by 2025, with a debt-to-asset ratio of 17.35% [11][12]. Product and Market Development - The company is focusing on expanding its product pipeline, with several projects in various clinical stages, including four in the NDA phase and three in Phase III clinical trials [4]. - New products like复立坦 and 信立汀他 have entered the national medical insurance catalog, laying a foundation for future growth [3]. - The company’s flagship product, 信立坦, continues to gain market share in the competitive hypertension drug market, particularly in grassroots markets [3].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Insights - In 2024, the company achieved operating revenue of 2.97 billion yuan, a year-on-year increase of 33.4%; net profit attributable to the parent company was 340 million yuan, up 31.7%; and net profit excluding non-recurring items was 330 million yuan, growing by 73.9%. In Q1 2025, the company reported operating revenue of 850 million yuan, a year-on-year growth of 28%; net profit attributable to the parent company was 140 million yuan, increasing by 22.1%; and net profit excluding non-recurring items was 130 million yuan, up 28.6% [2][4] Summary by Sections Business Performance - The company continues to solidify its big product strategy, with the main brand maintaining high growth. In 2024, revenue growth rates for each quarter were 39%, 19%, 26%, and 48%, with a significant acceleration in Q4. The main brand, Marubi, generated revenue of 2.06 billion yuan, a year-on-year increase of 31.7%. The two core products, the Little Red Pen Eye Cream and the Little Gold Needle, achieved GMV of 530 million yuan and 350 million yuan, respectively, with year-on-year growth of 146% and 96%. The Love Fire brand generated revenue of 910 million yuan, up 40.7%, with six foundation products each exceeding 100 million yuan in annual GMV [13] Financial Forecast - For 2025-2027, the company is expected to achieve net profits attributable to the parent company of 450 million yuan, 580 million yuan, and 750 million yuan, respectively, corresponding to EPS of 1.11 yuan, 1.44 yuan, and 1.87 yuan per share [13][17]

Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 2.02 billion yuan in 2024, representing a year-on-year growth of 4.3%, while the net profit attributable to shareholders was 660 million yuan, down 11.8% year-on-year. In Q1 2025, the revenue was 300 million yuan, a decline of 26.4% year-on-year, and the net profit attributable to shareholders was 90 million yuan, down 39.8% year-on-year [2][4] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 2.02 billion yuan, with a net profit of 660 million yuan. The revenue growth was primarily driven by the cosmetics segment, which saw a 7.5% increase year-on-year, while the medical device segment remained stable with a 0.3% increase [9] - For Q1 2025, the company experienced a significant revenue drop of 26.4% year-on-year, attributed to proactive channel and product optimization efforts [9] Product and Channel Strategy - The company has successfully expanded its product offerings, with several products achieving annual sales exceeding 100 million yuan. The online sales channel has also seen substantial growth, with a 20% increase in revenue [9] - The company is focusing on enhancing its brand presence in e-commerce platforms, which has contributed to a significant increase in online sales [9] Profitability Metrics - The overall gross margin for 2024 was 82%, with a slight decrease of 0.5 percentage points. The net profit margin decreased by 6 percentage points to 32.8%, primarily due to an increase in sales expense ratio [9] - In Q1 2025, the net profit margin further declined by 6.7 percentage points, influenced by a rise in sales expenses and adjustments in product pricing [9] Future Outlook - The company is expected to stabilize its revenue and profitability through the formation of repeat purchases of core products and the gradual establishment of e-commerce strategies. EPS forecasts for 2025, 2026, and 2027 are projected to be 1.74 yuan, 1.89 yuan, and 2.05 yuan respectively [9]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6] Core Views - The company reported a revenue of 5.736 billion yuan for 2024, representing a year-on-year growth of 3.87%, while the net profit attributable to shareholders was 500 million yuan, a decline of 33.53% year-on-year. For Q1 2025, the revenue was 949 million yuan, down 13.51% year-on-year, and the net profit attributable to shareholders was 28.34 million yuan, a decrease of 83.97% year-on-year [2][4] Summary by Sections Revenue Analysis - In 2024, the company's revenue from online, offline, and OMO channels was 3.91 billion, 1.27 billion, and 520 million yuan respectively, with year-on-year changes of 10%, -11%, and flat. The online channel outperformed the offline channel, with Tmall showing better performance than the market average [10] - The main brand, Winona, generated 4.91 billion yuan in revenue, a year-on-year decline of 5%, while smaller brands experienced high double-digit growth, contributing to overall revenue stability [10] Profitability Analysis - The gross profit margin for 2024 was 73.74%, remaining stable year-on-year. However, the sales expense ratio increased by 2.7 percentage points to 49.97%, and the management expense ratio rose by 1.5 percentage points to 8.94%. This led to a decline in the net profit margin from 13.7% to 8.8% [10] - In Q1 2025, the revenue decreased by 13.5%, but the gross profit margin improved by 5.4 percentage points to 77.5% due to operational optimizations and a focus on core products [10] Investment Recommendations - Despite the challenges in revenue and profit, the company is expected to see a recovery in profit margins due to ongoing inventory optimization and stable pricing for core products. The projected EPS for 2025-2027 is 1.66, 2.04, and 2.49 yuan respectively, supporting the "Buy" rating [10]

Investment Rating - The report maintains a "Buy" rating for Weichai Power [6] Core Views - Weichai Power reported a revenue of 57.464 billion yuan for Q1 2025, representing a year-on-year growth of 1.92%. The net profit attributable to shareholders was 2.711 billion yuan, up 4.27% year-on-year. The projected net profits for 2025-2027 are 12.763 billion, 14.473 billion, and 15.396 billion yuan, corresponding to PE ratios of 10.39X, 9.16X, and 8.61X respectively. The report cites the old-for-new policy support, stabilization and recovery in the heavy truck industry, and stable cash flow as reasons for the positive outlook [2][4][10]. Summary by Sections Financial Performance - In Q1 2025, Weichai Power achieved a revenue of 57.464 billion yuan, with a year-on-year increase of 1.92%. The net profit attributable to shareholders was 2.711 billion yuan, reflecting a 4.27% year-on-year growth. The heavy truck sales for Q1 were 265,000 units, showing a year-on-year increase of 21.0% [2][4][10]. Strategic Initiatives - The company is advancing six strategic directions aimed at long-term development, focusing on adjusting product, business, and market structures. This includes accelerating the transition to new energy and digital intelligence, and expanding into large-diameter, aftermarket, non-road vehicles, and export businesses. The demand for high-end large-diameter power generation products is expected to increase, particularly in sectors like 5G data centers and mining [10]. Investment Outlook - The report projects net profits for 2025-2027 at 12.763 billion, 14.473 billion, and 15.396 billion yuan, with corresponding PE ratios of 10.39X, 9.16X, and 8.61X. The combination of supportive policies, industry recovery, and stable cash flow positions Weichai Power as a high-dividend quality stock, justifying the "Buy" rating [2][10].

Investment Rating - The investment rating for the company is "Buy" and is maintained [7] Core Views - The company reported a significant improvement in operational performance, with Q1 2025 revenue reaching 1.469 billion yuan, a year-on-year increase of 24.69%. The net profit attributable to shareholders was 93 million yuan, up 2.00% year-on-year, while the net profit excluding non-recurring items was 88 million yuan, reflecting a 2.48% increase year-on-year. However, the operating cash flow net amount decreased by 25.44% to 122 million yuan [2][4] - The company is positioned as a global leader in intelligent operating system products and technologies, leveraging its strategic advantages to drive the development of the smart industry amid a new wave of intelligentization. A new growth curve is expected to gradually open up [2][4] Summary by Sections Financial Performance - In Q1 2025, the company achieved a revenue of 1.469 billion yuan, representing a 24.69% increase year-on-year. The gross profit margin for Q1 was 36.28%, down 3.54 percentage points year-on-year, primarily due to increased personnel costs as the workforce grew from 13,119 in 2023 to 15,031. Operating costs increased by 32.02% year-on-year. However, the gross margin showed a significant recovery, increasing by 6.74 percentage points compared to the previous quarter [4][10] - The sales expense ratio, R&D expense ratio, and management expense ratio for Q1 were 3.54%, 19.20%, and 9.37%, respectively, showing a decrease compared to the same period last year [10] Growth Strategy - The company has outlined three main growth curves: 1. Capitalizing on the emerging trend of mobile operating systems to enter a rapidly growing market. 2. Enhancing existing business with edge AI to benefit from the increasing penetration of terminal intelligence. 3. Combining edge AI with innovative businesses, such as mobile robotics platforms, to fully leverage the opportunities presented by edge intelligence [10] - Recent product launches, including Drip OS 1.0 Evo, TurboX AI glasses, and mobile robot AMR, highlight the company's breakthroughs in AI-native operating systems and edge intelligence [10] Market Positioning - The company is firmly committed to its "operating system + edge intelligence" strategy, with a strong positioning expected to open up a new growth curve. The company has established long-term collaborations with leading players in the industry, including chip manufacturers and cloud service providers, to expand its ecosystem [10] - The company is well-positioned in the smart industry, aligning its business layout with the trend of value growth shifting from cloud to edge, and is expected to benefit from every wave of terminal intelligence opportunities [10]

店均高速增长，开店节奏稳健，注重品牌系统性工程建设 Strong Average Store Growth, Steady Expansion Pace, Focusing on Systematic Brand Development 寇媛媛 Yuanyuan Kou 陈芳园 Ashley Chen [Table_Title] 研究报告 Research Report 26 May 2025 潮宏基 CHJ Industry (002345 CH) yy.kou@htisec.com ashley.fy.chen@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_summary] (Please see APPENDIX 1 for English summary) 事件：5 月 23 日，海通国际海外消费组调研潮宏基总部，参加公司高管交流会。公司管理层表示终端增速自 2024 年 四季度开始提升，2025 年 4 月份店均增速约 45%，5 月初至 5 月 20 日增速约为 30%。5 月门店人流量在五一假期后 有所下滑，主要是受节日透支效应影响。 ...